iShares Global Tech ETF vs Nuwellis Inc — how do they compare? iShares Global Tech ETF trades at $139.33, while Nuwellis Inc trades at $1.49 (market cap $522.76K). The key difference: iShares Global Tech ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| IXN | NUWE | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $149.74 | $220.50 |
52-Week Low | $94.42 | $1.42 |
Market Cap | — | $522.76K |
Enterprise Value | — | -$1.29M |
Signals from Pluang's Aura AI — not financial advice
IXN trades at $140.87, up 1.09% today, with a bullish technical signal from moving averages. The stock is near resistance at $141, with RSI indicating potential overbought conditions. Recent news highlights its global tech exposure, including AI developments from international firms.
Outlook is cautious due to high valuations and concentration risk in tech holdings. Opportunities exist from AI growth, but risks include stretched earnings expectations and market volatility. Analyst sentiment is mixed, favoring a hold rating for a better entry point.
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
Trailing returns across standard periods
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →